Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JMT108 in advanced malignant tumors
NCT06877650Phase 2
Key facts
- Status
- Recruiting
- Start
- Apr 2025
- Primary completion
- Mar 2028
- Countries
- 1
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Drugs
- JMT108
- Conditions
- cancer
01
Overview
Phase 2, open-label, single-arm trial of JMT108 in cancer, sponsored by Shanghai Jinmante Biotechnology Co., Ltd. Primary endpoints: Dose-Limiting Toxicity at 28 days and Adverse Events at 1 year. Started Apr 2025; status: recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
JMT108 (Monotherapy and Combination)
JMT108 administered as monotherapy or in combination with pembrolizumab or ivonescimab, IV Q3W
03
Who it enrols
Adults ≥18 years with histologically/cytologically confirmed advanced malignant tumors unresponsive or intolerant to standard of care, or NSCLC without sensitive gene mutations. ECOG 0-2 (0-1 for Stage II), life expectancy ≥3 months, adequate organ function, no active CNS metastases, no autoimmune disease, no prior Grade ≥3 immune-related AEs
04
Endpoints
Primary
Dose-Limiting Toxicity
Adverse Events
Secondary
Maximum Plasma Concentration
Beyond the preview
Go deeper on NCT06877650.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06877650.